We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Avacta Group Plc | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 45.30 | 45.00 | 45.50 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 10.06M | -39.19M | -0.1382 | -3.27 | 128.34M |
From Apr 2019 to Apr 2024
TIDMAVCT
RNS Number : 6792N
Avacta Group PLC
21 January 2019
21 January 2019
Avacta Group plc
("Avacta", the "Group" or the "Company")
Result of Annual General Meeting
Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.
The full text of each resolution is set out in the Notice of Annual General Meeting, included in the 2018 Annual Report, which is available on the Company's website www.avacta.com.
- Ends -
For further information from Avacta Group plc, please contact:
Hot Features
Premium
Avacta Group plc Tel: +44 (0) 844 414 0452
Alastair Smith, Chief Executive https://www.avacta.com
Officer
Tony Gardiner, Chief Financial Officer
finnCap Ltd Tel: +44 (0) 207 220 0500
Geoff Nash / Giles Rolls - Nominated www.finncap.com
Adviser
Tim Redfern - ECM
Tel: +44 (0) 203 705 9318
WG Partners Tel: +44 (0) 203 705 9217
Nigel Birks / Nigel Barnes www.wgpartners.co.uk
David Wilson / Claes Spang
Turner Pope Investments Tel: 020 3621 4120
James Pope james@turnerpope.com
Zyme Communications (Trade and Regional Tel: +44 (0)7787 502 947
Media) katie.odgaard@zymecommunications.com
Katie Odgaard
Yellow Jersey (Financial Media and Tel: +44 (0)7764 947137
IR) Tel: +44 (0)7544 275882
Sarah Hollins avacta@yellowjerseypr.com
Harriet Jackson
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer(R) technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer(R) technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer(R) reagents through licensing to developers of life sciences research tools and diagnostics.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
RAGPGUPWGUPBGAG
(END) Dow Jones Newswires
January 21, 2019 10:40 ET (15:40 GMT)
1 Year Avacta Chart |
1 Month Avacta Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
